Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Illumina : Amendment to Combined Synopsis/Solicitation - Illumina Sequencer Maintenance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/05/2016 | 02:36pm CET

Notice Type: Amendment to Combined Synopsis/Solicitation

Posted Date: 02-DEC-16

Office Address: Department of Health and Human Services; National Institutes of Health; National Institute of Child Health and Human Development; Contracts Management Branch6710B Rockledge Dr., Suite 1124, MSC7000 Bethesda MD 20892-7510

Subject: Illumina Sequencer Maintenance

Classification Code: J - Maintenance, repair & rebuilding of equipment

Solicitation Number: NICHD-17-017

Contact: Tina Robinson, Phone 301-443-7796, Fax 301-480-8844, Email tr207f@nih.gov

Setaside: N/AN/A

Place of Performance (address): 9000 Rockville PikeBethesda, MD

Place of Performance (zipcode): 20892

Place of Performance Country: US

Description: Department of Health and Human Services

National Institutes of Health

National Institute of Child Health and Human Development

Notice modified to add Technical Support hours and Standard to On-site coverage. There are no other changes to this notice. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NICHD-17-017 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-92. The North American Industry Classification (NAICS) Code is 811219 and the business size standard is $20.5m. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) intends to contract on a sole source basis with Illumina Inc., 5200 Illumina Way, San Diego, CA 92122 to procure a fixed priced one year service agreement for the following Illumina instruments: 1. Product Care HiSeq(R) 2500 DNA sequencer (sn: D00762) Comprehensive Plan: Includes full coverage for parts, labor and travel; Reagent /kits replacement upon Hardware failures @ no charge, 1PM; Remote Technical Support; Service technician/personal shall acknowledge repair request w/in 24 business hours, priority scheduling for service calls , on-site responses shall occur w/in three business days when required, Hardware/Software updates: On-site applications support; advanced application training, Field Application Scientist Support - Standard On-Site coverage hours/days are 5x18 (M-F, 8:00 am to 5:00 pm local time, excluding holidays) phone support and 5x24 email access to Technical Support hours Sunday 3:30pm to Friday 5:00pm PST. Replacement parts/reagents and hardware/software updates/upgrades provided must be Original Equipment Manufacturer (OEM) certified. Coverage period start date mid to late December 2016. 2. Product Care MiSeq(R) DNA sequencer (sn: M04210) Comprehensive Plan: Includes full coverage for parts, labor and travel; Reagent/kits replacement upon Hardware failures @ no charge: Remote Technical Support; Service technician/personal shall acknowledge repair request w/in 24 business hours, priority scheduling for service calls, on-site responses shall occur w/in three business days when required, Hardware/Software updates: On-site applications support; advanced application training - Standard On-site coverage hours/days are 5x18 (M-F, 8:00 am to 5:00 pm local time, excluding holidays) phone support and 5x24 email access to Technical Support hours Sunday 3:30pm to Friday 5:00pm PST. Replacement parts/reagents and hardware/software updates/upgrades provided must be Original Equipment Manufacturer (OEM) certified. Coverage period start date mid to late December 2016. Illumina is the sole provider of service for the Illumina pieces of equipment. Only Illumina, Inc. has technical service representatives who receive comprehensive and on-going factory training and regular technical updates, as well as having direct access to original manufacturer's parts to help maintain the instruments in optimal condition. Illumina can engage directly with the engineers that designed the instruments, to help resolve challenging technical support needs. These instruments by virtue of their complex nature containing multiple individual components require regular maintenance as well as alignment and calibrations which can only be carried out by dedicated knowledgeable engineers trained specifically by the manufacturer, Illumina Inc. No other vendor has either access or has to ability to provide these specialized parts. These sequencers are mission critical for the scientific experiments undertaken in the individual laboratories where these devices are maintained in NICHD laboratories. Furthermore, Illumina trains only their engineers on the functions and system control of all these integrated devices. Illumina does not offer this training to anyone outside of their personnel resources. The priority scheduling is very important for the proper upkeep and functionality of these complex sequencers. Thus, timely service is crucial in the functioning of these two sequencers. Acquisition of service contract offering from other entities/third parties providers can lead to substantive problems getting timely service engineer dispatched and can lead to down times on devices. NIH is a research organization where critical experiments require many weeks of tissue culture preparations and also in animal breeding programs, etc. thus such delays will impose a very large financial burden on research laboratories which are hurting for research funds in the first place. Waste of experimental reagents, animals and human resources are the biggest problem in addition to reduction in research productivities. The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. This notice of intent is not a request for competitive quotations however, all responses received, within twelve days from the date of publication of this synopsis will be considered by the Government. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation: The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The factors used to evaluate offers are (1) technical capability to provide all services/consumables, etc. outline above (2) price; and (3) past performance. Technical and past performance, when combined, are significantly more important than cost or price.- Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of furnishing the government with the service and products specified in this synopsis should submit a copy of their quotation to the below address or via email to robinsti@mail.nih.gov. Offers must also be accompanied by descriptive literature, warranties and other information that demonstrates that the offer meets all of the foregoing requirements. Quotations will be due twelve calendar days from the publication date of this synopsis or by December 12, 2016 by 10am EST. via email or postal mail or other mailing services. The quotation must reference "Solicitation number" NICHD-17-017. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, MSC 1159B, Bethesda, MD 20892. Attention: Tina Robinson, by the date and time mentioned above. Any questions must be sent via email to robinsti@mail.nih.gov and must include solicitation# NICHD-17-017 in the subject line of email. Faxed copies/responses will not be accepted. Note: In order to receive an award, contractor must be registered and have valid certification in the SAM database @www.sam.gov.

Link/URL: https://www.fbo.gov/spg/HHS/NIH/NICHD/NICHD-17-017/listing.html

(c) 2013 Federal Information & News Dispatch, Inc., source Federal Documents

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ILLUMINA, INC.
12/05 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina Sequencer Main..
12/05 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina NextSeq 500 Ma..
12/02 ILLUMINA : Mass Spectrometry Adopted by Clinical Laboratories Around the World
12/02 ILLUMINA : Combine Solicitation - Illumina NextSeq 500 Maintenance
12/02 ILLUMINA : Combine Solicitation - Illumina Sequencer Maintenance
12/01 ILLUMINA : Launches iHope Program to Identify Causes of Undiagnosed Genetic Dise..
11/29 ILLUMINA INC : Change in Directors or Principal Officers (form 8-K)
11/29 ILLUMINA : Contributes to ClinVar Database
11/28 ILLUMINA : to Webcast Live Presentation at the Citi Global Healthcare Conference
11/22 ILLUMINA : and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic D..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
12/05 Aixtron could revive takeover despite U.S. block
12/02 Deals scuppered by U.S. regulatory scrutiny
11/29 European spin-offs and carve-outs
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
06:48a New finance chief at Illumina
12/04 WEEK IN REVIEW : Suzhou's Innovent Biologics Announces Record $260 Million Fundi..
12/01 More Medtech Venture Cash Goes Into Series A Rounds
11/29 Illumina clinical genomics chief bids adieu
11/25 Where Will CRISPR-Cas9 Work First?
Advertisement
Financials ($)
Sales 2016 2 390 M
EBIT 2016 675 M
Net income 2016 435 M
Finance 2016 124 M
Yield 2016 -
P/E ratio 2016 42,76
P/E ratio 2017 37,52
EV / Sales 2016 7,72x
EV / Sales 2017 6,89x
Capitalization 18 568 M
More Financials
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 144 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Marc A. Stapley EVP, Chief Financial & Administrative Officer
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Norman Fjeldheim Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.-34.15%18 568
THERMO FISHER SCIENTIF..1.23%56 722
DANAHER CORPORATION8.49%53 524
BOSTON SCIENTIFIC CORP..12.85%28 336
PHILIPS15.41%27 639
INTUITIVE SURGICAL, IN..13.81%24 085
More Results